Almirall, LLC

Zelsuvmi's approval for molluscum contagiosum tops Healio's most-read FDA approvals in dermatology for 2024, with other notable approvals including Xeomin, Klisyri, Zoryve, and more.

Absci announced updates on its AI-driven drug creation programs, including ABS-201 for androgenic alopecia, ABS-101 for anti-TL1A, ABS-301 for immuno-oncology, and ABS-501 for anti-HER2. The company also highlighted a breakthrough in designing antibodies targeting the HIV 'caldera' region, potentially aiding universal HIV vaccine development.

Propionic acid deficiency may contribute to multiple sclerosis (MS) pathology. Propionate shows beneficial effects on immune, peripheral, and central nervous systems in MS patients, potentially improving outcomes when used with immune-modulating therapy. Further large clinical trials are necessary to evaluate its efficacy and safety.

Almirall's CEO Carlos Gallardo reports the successful launch of Lilly-partnered atopic dermatitis drug Ebglyss in Germany and other European countries, achieving desired pricing.

Eli Lilly’s EBGLYSS showed improvement in skin condition and itch relief in moderate-to-severe atopic dermatitis patients, particularly those unresponsive to dupilumab, according to the Phase IIIb ADapt study. 57% achieved EASI-75 by week 16, rising to 60% by week 24, with 52% experiencing clear or almost clear facial dermatitis by week 24. The therapy’s safety profile remained consistent with previous trials.

Upadacitinib (Rinvoq) demonstrated a favorable long-term benefit-risk profile through 76 weeks in adolescents with moderate to severe atopic dermatitis, achieving EASI-75 in 84-96% of patients across three phase III trials. Both 15 mg and 30 mg doses met primary endpoints, with acne and nausea as most common adverse events. Long-term outcomes were consistent with known AE profile, with no new signals observed. The analysis involved 542 adolescents, with data gathered from August 2018 to April 2022.

Tirbanibulin ointment 1% demonstrated efficacy and tolerability in treating actinic keratosis on fields up to 100 cm², following FDA approval in June 2024. The phase 3 study involved 105 patients, showing reduced AKs and common local tolerability signs like erythema and flaking/scaling. The treatment was well-tolerated, with no cosmetic changes noted, supporting its use in larger areas.

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) showed sustained disease control for up to three years in 80%+ of moderate-to-severe atopic dermatitis patients, with 84% on monthly and 83% on bi-weekly regimens maintaining clear or almost clear skin. The treatment received FDA approval earlier this month.

Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.